Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
Dainippon Pharmaceutical
|
| gptkbp:awards |
various industry awards
|
| gptkbp:ceo |
Masayo Tada
|
| gptkbp:clinical_trial |
ongoing
Phase III trials Phase I trials Phase II trials conducts clinical research |
| gptkbp:collaborations |
international research collaborations
biotech companies |
| gptkbp:community_engagement |
healthcare programs
|
| gptkbp:community_outreach |
health education initiatives
|
| gptkbp:employees |
over 7,000
|
| gptkbp:financial_performance |
strong financial performance
|
| gptkbp:focus |
research and development
|
| gptkbp:founded |
gptkb:2005
1897 |
| gptkbp:global_presence |
over 20 countries
|
| gptkbp:headcount |
7,000+
|
| gptkbp:headquarters |
gptkb:Osaka,_Japan
|
| gptkbp:healthcare |
prescription drugs
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sumitomo Dainippon Pharma
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:instruction_set |
multiple drug candidates
|
| gptkbp:invention |
numerous pharmaceutical patents
|
| gptkbp:investment |
institutional investors
R& D initiatives |
| gptkbp:market |
global
|
| gptkbp:market_cap |
approximately $10 billion
|
| gptkbp:parent_company |
gptkb:Sumitomo_Group
|
| gptkbp:partnerships |
global pharmaceutical companies
various academic institutions |
| gptkbp:products |
gptkb:pharmaceuticals
medicines |
| gptkbp:research_areas |
neurology
oncology psychiatry cardiovascular |
| gptkbp:research_focus |
mental health
autoimmune diseases biologics infectious diseases pain management small molecules |
| gptkbp:research_institutes |
Sumitomo Dainippon Pharma Research Institute
|
| gptkbp:revenue |
approximately $2 billion
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stock_symbol |
4506
|
| gptkbp:strategic_goals |
sustainable growth
innovation in healthcare expansion in emerging markets enhancing patient access |
| gptkbp:subsidiaries |
Dainippon Sumitomo Pharma America
|
| gptkbp:sustainability |
environmental initiatives
|
| gptkbp:therapeutics |
develops therapeutics for unmet needs
|
| gptkbp:website |
www.ds-pharma.com
|
| gptkbp:bfsParent |
gptkb:Sunovion_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|